<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413020</url>
  </required_header>
  <id_info>
    <org_study_id>rjkls2017198</org_study_id>
    <nct_id>NCT03413020</nct_id>
  </id_info>
  <brief_title>Tailored Therapy for Helicobacter Pylori Rescue Treatment</brief_title>
  <official_title>Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With increasing antibiotic resistance and unsatisfactory results of empiric eradication
      regimens, tailored therapy may be the best choice to achieve high efficacy for rescue
      treatment. This study aimed to evaluate the eradication rates, safety, and compliance of
      antimicrobial susceptibility-based tailored therapy for rescue treatment in patients with
      Helicobacter pylori infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>Six weeks after completion of therapy</time_frame>
    <description>Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (&lt;4‰) (4‰ as the cutoff value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Within 7 days after completion of therapy</time_frame>
    <description>The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as &quot;mild&quot; (transient and well tolerated), &quot;moderate&quot; (causing discomfort and partially interfering with daily activities), or &quot;severe&quot; (causing considerable interference with daily activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>Within 7 days after completion of therapy</time_frame>
    <description>Compliance was defined as poor when they had taken less than 80% of the total medication.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Medical cost per patient of tailored therapy</measure>
    <time_frame>Two months after completion of therapy</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Tailored Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
    <description>proton pump inhibitor</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bismuth Potassium Citrate</intervention_name>
    <description>gastric mucosal protective drug with anti-H. pylori effect</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>antibiotic for H. pylori eradication</description>
    <arm_group_label>Tailored Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with non-ulcer functional dyspepsia or scarred peptic ulcer disease

          -  Previous failures of H. pylori eradication therapy and need rescue therapy

          -  Ability and willingness to participate in the study and to sign and give informed
             consent

          -  Confirmed H. pylori infection

        Exclusion Criteria:

          -  Less than 18 years old

          -  With previous gastric surgery

          -  Major systemic diseases

          -  Pregnancy or lactation

          -  Allergy to any of the study drugs

          -  Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lou Yu, M.D.</last_name>
    <phone>86+18202105517</phone>
    <email>yulousjtu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Yu, M.D.</last_name>
      <phone>86+18202105517</phone>
      <email>yulousjtu@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Lu, M.D.,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lou Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao Liang, M.D.,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaohua Long, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laisheng Luo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Hong Lu, MD</investigator_full_name>
    <investigator_title>Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Rescue therapy</keyword>
  <keyword>Tailored therapy</keyword>
  <keyword>Antimicrobial susceptibility testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

